The prognostic impact of neoadjuvant chemotherapy for resectable/borderline resectable pancreatic cancer in the elderly patients

The prognostic impact of neoadjuvant chemotherapy for resectable/borderline resectable pancreatic cancer in the elderly patients - The prognostic impact of neoadjuvant chemotherapy for resectable/borderline resectable pancreatic cancer in the elderly patients

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000052925

Enrollment

Registered

2023-11-27

Start date

2021-05-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who experience neoadjuvant chemotherapy for resectable/borderline resectable pancreatic cancer The patients who do not refuse to participate in this study

Exclusion criteria

Exclusion criteria: Other patients who are judged by the principal investigator to be unsuitable as research subjects.

Design outcomes

Primary

Measure	Time frame
Relative dose intensity of neoadjuvant chemotherapy	—

Countries

Japan

Contacts

Public ContactMasaaki Minagawa

Juntendo University Hospital Hepatobiliary-Pancreatic Surgery

m-minagawa@juntendo.ac.jp03-3813-3111

Outcome results